Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma

Abstract

Gefitinib was well tolerated, but the response rate was poor in this heavily pretreated study population, and its use in NPC is not recommended outside the context of clinical trial.